2005 - Cambridge Antibody Technology
A developer of human monoclonal antibody therapeutics, CAT was the first UK biotech to jointly develop a 'blockbuster' drug. The company was acquired by AstraZeneca in 2006 for £702m and subsequently incorporated into MedImmune, which continues to grow in Cambridge.
CAT was founded in 1989 by, among others, Dr David Chiswell, Dr Greg Winter and the Medical Research Council. AstraZeneca has kept its promise to grow the business globlly from Cambridge and has continued to expand at Granta Park.